Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.79 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.35 |
| ▸ | SLC10A2 | Q12908 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4617212 | 0.98 | NR1H4 (0.80) | NR1H4PTPN1SLC10A2KMT2AATM | |
| SCHEMBL5691778 | 0.94 | NR1H4 (0.74) | NR1H4PTPN1SLC10A2CTSD | |
| SCHEMBL5743635 | 0.93 | NR1H4 (0.83) | NR1H4SLC10A2KMT2AATM | |
| SCHEMBL25249701 | 0.93 | NR1H4 (0.77) | NR1H4PTPN1SLC10A2CTSD | |
| SCHEMBL26235945 | 0.92 | NR1H4 (0.79) | NR1H4SLC10A2KMT2AATM | |
| SCHEMBL919321 | 0.92 | NR1H4 (0.79) | NR1H4SLC10A2KMT2AATM | |
| Ammonia Solution, Strong SCHEMBL5742064 | 0.92 | NR1H4 (0.78) | NR1H4SLC10A2KMT2AATM | |
| Ammonia Solution, Strong SCHEMBL5742061 | 0.92 | NR1H4 (0.78) | NR1H4SLC10A2KMT2AATM | |
| SCHEMBL4615546 | 0.91 | NR1H4 (0.80) | NR1H4SLC10A2KMT2AATMCTSD | |
| SCHEMBL4731985 | 0.91 | NR1H4 (0.79) | NR1H4SLC10A2KMT2AATMCTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2023-07-06 | — | — | US | disclosed |
| EP-1851197-A2 | PHENYLAZETIDINONE DERIVATIVES | Microbia, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212211-A1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF HYPERCHOLEMIA AND CHOLESTATIC LIVER DISEASE | SLC10A1, SLC10A2, ABCB11 | NR1H4 4/4885PTPN1 1990/4885SLC10A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.